Funding for this research was provided by:
Hochschule für angewandte Wissenschaften Hof
Received: 26 November 2020
Accepted: 12 April 2021
First Online: 22 April 2021
: The study was approved by the Ethics Committee of the Medical Faculty of the University of Rostock (reference number A 2017–0091). We confirm that all methods were performed in accordance with the relevant guidelines and regulations.When collecting the data, neither the name and address nor the exact date of birth is recorded. Furthermore, we encourage the participants to use a neutral email address which does not disclose their names. Since the data was collected largely anonymously, there were no further conditions imposed by the ethics committee.During the registration process, participants are informed about privacy issues. A data protection declaration complies with the requirements of the German data protection and data security laws.With their registration, they give their consent to participate. We thus received the informed consent of all participants in the study.As described in [CitationRef removed], no data analysis starts directly from the migraine attack database. Instead, all necessary attack data are extracted from the database while skipping the link to the email address. This ensures that researchers analyzing the data cannot reproduce the connection between the attack data and the participants having reported the attacks.
: Not applicable
: Dr. Gaul has received honoraria for consulting and lectures within the past 3 years from Allergan Pharma, Lilly Germany, Novartis Pharma, Hormosan Pharma, Grünenthal, Sanofi-Aventis and TEVA. He does not hold any stocks of pharmaceutical companies. All other authors declare that there is no conflict of interest.